The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 11, 2012, Pages 1293-1297

  Liu, Qian ^a,b   Dang, Da Sheng ^a   Chen, Yu Feng ^a   Yan, Ming ^a   Shi, Guo Bing ^a   Zhao, Qing Chun ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CYTOCHROME P450 2C19; OMEPRAZOLE; PLACEBO;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CORONARY STENT; ELECTIVE SURGERY; EX VIVO STUDY; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; BLOOD PLATELETS; DRUG INTERACTIONS; HUMANS; MALE; OMEPRAZOLE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; YOUNG ADULT;

EID: 84868018512     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0119     Document Type: Article

References (29)

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. (2007) Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505-1516. (Pubitemid 46517957)
2. Barragan P, Bouvier JL, Roquebert PO, et al. (2003) Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59:295-302. (Pubitemid 36792384)
3. Bhatt DL, Scheiman J, Abraham NS, et al. (2008) ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID Use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 52:1502-1517.
4. Buonamici P, Marcucci R, Migliorini A, et al. (2007) Impact of platelet reactivity after clopidogrel administration on drugeluting stent thrombosis. J Am Coll Cardiol 49:2312-2317. (Pubitemid 46891710)
5. Chen BL, Zhang W, Li Q, et al. (2008) Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms. Clin Exp Pharmacol Physiol 35:904-908. (Pubitemid 351953054)
6. Cuisset T, Frere C, Quilici J, et al. (2006) High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4:542-549.
7. Cuisset T, Frere C, Quilici J, et al. (2009) Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. The PACA (proton pump inhibitors and clopidogrel association) prospective randomized study. J Am Coll Cardiol 54:1149-1153.
8. Cuisset T, Hamilos M, Sarma J, et al. (2008) Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 101:1700-1703.
9. Desta Z, Zhao X, Shin JG, et al. (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958. (Pubitemid 35168437)
10. Dojo M, Azuma T, Saito T, et al. (2001) Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Digest Liver Dis 33:671-675. (Pubitemid 33107666)
11. Frere C, Cuisset T, Morange PE, et al. (2008) Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 101:1088-1093.
12. Gerschutz GP, Bkatt DL (2001) The clopidogrel in unstable angina to prevent recurrent events trial (CURE) study: effects of clopidogrel in addition to aspirin in patients with acutecoronary syndromes without ST-segment elevation. N Engl J Med 345:494-502.
13. Gilard M, Arnaud B, Cornily JC, et al. (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study. J Am Coll Cardiol 51:256-260.
14. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355. (Pubitemid 32939439)
15. Hulot JS, Bura A, Villard E, et al. (2006) Cytochrome P450 2C19 lossof-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247. (Pubitemid 44497506)
16. Ingelman-Sundberg M, Daly AK, Nebert DW (2009) Human cytochrome P450 allele nomenclature committee. Available at www.cypalleles.ki.se/(accessed 25 Aug. 2009).
17. Ishizaki T, Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13 Suppl 3:27-36. (Pubitemid 29389409)
18. Jacqz E, Dulac H, Mathieu H (1988) Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 35:167-171.
19. Juurlink DN, Gomes T, Ko DT, et al. (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180:713-718.
20. Kazui M, Nishiya Y, Ishizuka T, et al. (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92-99.
21. Ko JW, Sukhova N, Thacker D, et al. (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862. (Pubitemid 27318604)
22. Kubota T, Chiba K, Ishizaki T (1996) Genotyping of S-mephenytoin 4-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661-666. (Pubitemid 27025913)
23. Lau WC, Gurbel PA, Watkins PB, et al. (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109:166-171. (Pubitemid 38114134)
24. Lau WC, Waskell LA, Watkins PB, et al. (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107:32-37. (Pubitemid 36070929)
25. Matetzky S, Shenkman B, Guetta V, et al. (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171-3175.
26. Mega JL, Close SL, Wiviott SD, et al. (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-364.
27. Shu Y, Zhou HH (2000) Individual and ethnic differences in CYP2C19 activity in Chinese populations. Acta Pharmacol Sin 21:193-199. (Pubitemid 30160975)
28. Siller-Matula J, Spiel A, Lang I, et al. (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157:148.e1-148.e5.
29. Simon T, Verstuyft C, Mary-Krause M, et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Eng J Med 360:411-413.